Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.
Translationeel Onderzoek van Gastro-enterologische Aandoeningen (T.A.R.G.I.D.), Gasthuisberg University Hospital, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
Medicina (Kaunas). 2023 Mar 17;59(3):594. doi: 10.3390/medicina59030594.
Metabolic-dysfunction-associated fatty liver disease (MAFLD) is the recent nomenclature designation that associates the condition of non-alcoholic fatty liver disease (NAFLD) with metabolic dysfunction. Its diagnosis has been debated in the recent period and is generally associated with a diagnosis of steatosis and at least one pathologic condition among overweight/obesity, type 2 diabetes mellitus, and metabolic dysregulation. Its pathogenesis is defined by a "multiple-hit" model and is associated with alteration or dysbiosis of the gut microbiota. The pathogenic role of dysbiosis of the gut microbiota has been investigated in many diseases, including obesity, type 2 diabetes mellitus, and NAFLD. However, only a few works correlate it with MAFLD, although common pathogenetic links to these diseases are suspected. This review underlines the most recurrent changes in the gut microbiota of patients with MAFLD, while also evidencing possible pathogenetic links.
代谢相关脂肪性肝病(MAFLD)是最近的命名指定,将非酒精性脂肪性肝病(NAFLD)的情况与代谢功能障碍联系起来。在最近一段时间,其诊断一直存在争议,通常与脂肪变性的诊断以及超重/肥胖、2 型糖尿病和代谢失调中的至少一种病理状况相关。其发病机制由“多打击”模型定义,并与肠道微生物组的改变或失调相关。肠道微生物组的失调在许多疾病中的致病作用已经得到了研究,包括肥胖、2 型糖尿病和 NAFLD。然而,只有少数研究将其与 MAFLD 相关联,尽管这些疾病之间存在共同的发病机制联系。这篇综述强调了 MAFLD 患者肠道微生物组最常见的变化,同时也证明了可能的发病机制联系。